Journal of Pharmacology, Genetics and Molecular Biology (JPGMB)
ISSN: 3049-3757 | Vol. 02, Issue-02, March-April, 2026

Microfluidics in Pharmaceutical Nanomanufacturing: Towards Scalable and Controlled Drug Delivery

Mahesh K. Gaidhane[1*], Shambhu Khamhari[2], Sabeen Fatma[3], S. Mohamed Rabeek[4], Sonam Soni[5]

[1]Shri Lemdeo Patil Mahavidyalaya, Mandhal, RTM Nagpur University, Nagpur (MS), Pin: 441210
[2]Career College of Pharmacy, Raigarh, Chhattisgarh, India
[3]Chaudhary Charan Singh University, Meerut, UP, India
[4]Jamal Mohamed College (Autonomous), Affiliated to Bharathidasan University, Trichy - 20, Tamil Nadu, India
[5]University College of Pharmacy CSVTU, Bhilai, Pin: 491107, Chhattisgarh, India

***Corresponding Author E-mail: sonam.pharma16@gmail.com**

Abstract:

Microfluidic technology has emerged as a transformative platform in pharmaceutical nanomanufacturing, offering unprecedented control over the synthesis of nanoscale drug delivery systems. Traditional bulk manufacturing techniques often suffer from poor reproducibility, wide size distributions, and limited scalability, restricting their utility for clinical-grade nanoparticle production. In contrast, microfluidics enables precise manipulation of fluids under laminar flow, facilitating diffusion-driven mixing, rapid nucleation, and consistent particle formation across diverse nanocarriers including polymeric nanoparticles, lipid-based systems, inorganic materials, and hybrid or stimuli-responsive designs. The integration of real-time analytics, automated process optimization, and advanced microreactor geometries further enhances the ability to tailor nanoparticle properties such as size, polydispersity, and surface functionality. Recent advances in flow rate control, parallelization, and device engineering have accelerated the transition of microfluidics from laboratory research to scalable industrial production, exemplified by its successful application in large-scale mRNA lipid nanoparticle manufacturing. Emerging synergies with AI/ML tools, organ-on-chip platforms, 3D printing, and IoT-enabled continuous-flow systems are pushing microfluidic nanomanufacturing toward fully autonomous, high-throughput factories. Despite challenges related to device fouling, material compatibility, cost, and regulatory frameworks, microfluidics is poised to become a cornerstone of next-generation drug delivery, enabling highly controlled, customizable, and clinically translatable nanomedicine.

Keywords

Microfluidics; Nanomanufacturing; Drug delivery; Lipid nanoparticles; Polymeric nanoparticles; Continuous-flow synthesis; Precision nanomedicine.

Received: Jan. 08, 2026 **Revised: Feb. 18, 2026** **Accepted: March. 24, 2026** **Published: April 10, 2026**

DOI: https://doi.org/10.64062/JPGMB.Vol2.Issue2.4

https://jpgmb.com/1/issue/archive

ISSN: 3049-3757 | Vol. 02, Issue-02, March-April | 2026

1. Introduction

Nanomedicine has rapidly evolved into one of the most promising frontiers in modern therapeutics, driven by the growing need for precise, efficient, and patient-centric nanoscale drug delivery systems. These advanced formulations enable targeted transport, controlled release, and improved bioavailability, making them indispensable for treating complex diseases such as cancer, infectious disorders, and neurological conditions [1-2]. However, traditional bulk nanomanufacturing techniques—such as solvent evaporation, high-energy homogenization, and batch nanoprecipitation—often suffer from major limitations, including poor reproducibility, wide particle size distribution, inefficient encapsulation, and limited control over physicochemical properties. These challenges restrict scalability and hinder clinical translation, creating a pressing demand for more reliable production technologies [3-4].

In this context, microfluidics has emerged as a transformative platform capable of overcoming the bottlenecks associated with conventional manufacturing. By leveraging precise laminar flow conditions, rapid mixing, and tunable reaction environments, microfluidic systems enable highly controlled, continuous, and reproducible synthesis of nanoparticles with remarkable uniformity. This review explores the growing role of microfluidic technologies in pharmaceutical nanomanufacturing, highlighting their advantages, operational mechanisms, and potential to revolutionize scalable drug delivery. The aim is to provide a comprehensive overview of current advancements, existing challenges, and future opportunities that position microfluidics as a key enabler of next-generation nanomedicine [5-6].

2. Fundamentals of Microfluidic Technology

Microfluidic technology operates on the controlled manipulation of fluids within microscale channels, where flow behavior is dominated by laminar characteristics rather than turbulence. At these dimensions, the Reynold's number remains extremely low, causing fluids to flow in parallel streams with mixing governed primarily by molecular diffusion. This predictable flow environment enables precise control over reaction kinetics, mixing rates, and nanoparticle nucleation events—features that are essential for reproducible nanomanufacturing. Microfluidic devices are typically constructed using various channel architectures such as T-junctions, Y-shaped channels, and flow-focusing geometries, each designed to regulate fluid interaction and enhance mixing efficiency [7-8]. These geometries play a key role in dictating particle size, uniformity, and encapsulation behavior during nanoparticle synthesis.

The fabrication of microfluidic chips relies on diverse materials, including polydimethylsiloxane (PDMS) for its elasticity and optical transparency, glass and silicon for their chemical resistance and structural stability, and thermoplastics such as PMMA and COC for scalable and low-cost mass production. Together, these substrates support a wide range of chemical and biological applications while ensuring compatibility with pharmaceutical manufacturing. Compared to traditional bulk methods, microfluidic systems offer several compelling advantages: they require minimal reagent volumes, provide exceptional precision in controlling formulation parameters, and can be readily integrated with automation and real-time monitoring tools [8-9]. These benefits position microfluidics as a superior and highly adaptable platform for next-generation nanomedicine development.

3. Microfluidics for Nanoparticle Synthesis

Microfluidic platforms have become powerful tools for producing a wide spectrum of nanoparticles with exceptional precision and reproducibility. By exploiting controlled microscale mixing, rapid nucleation, and tightly regulated reaction environments, these systems enable the synthesis of nanocarriers with uniform size, narrow polydispersity, and customizable physicochemical properties—features that are often difficult to achieve through traditional batch-based approaches. The versatility of microfluidics allows it to support the fabrication of polymeric, lipid-based, inorganic, and hybrid nanoparticles, each tailored for specific drug delivery applications [10-11].

3.1 Polymeric Nanoparticles

Polymeric nanoparticles are commonly produced in microfluidic devices through nanoprecipitation, a process that relies on the rapid mixing of a polymer solution with a non-solvent to induce particle formation. Microfluidics enhances this process by ensuring controlled solvent–antisolvent interactions, allowing precise regulation of particle size, morphology, and monodispersity. Widely used polymers—including PLGA for controlled release, PEGylated systems for prolonged circulation, and chitosan for mucoadhesive or targeted delivery—benefit greatly from microfluidic fabrication. The ability to fine-tune flow rates, mixing geometry, and polymer concentration enables researchers to engineer nanoparticles with tailored surface characteristics and optimized drug loading efficiencies [12-13].

3.2 Lipid-Based Nanoparticles

Microfluidics has significantly advanced the production of lipid-based nanocarriers such as liposomes, solid lipid nanoparticles, and especially lipid nanoparticles (LNPs), which have become central to modern nucleic acid delivery. The rapid and controlled microfluidic mixing of lipids with aqueous buffers drives the self-assembly of uniform lipid structures, making this approach ideal for scalable mRNA–LNP production, as demonstrated in recent vaccine technologies. Microfluidic synthesis enhances encapsulation efficiency, reduces batch-to-batch

variability, and supports continuous manufacturing, providing a scalable route to high-quality lipid nanoparticles suitable for clinical translation [14-15].

3.3 Inorganic Nanoparticles

For inorganic nanoparticles such as gold nanoparticles, silica nanoparticles, and quantum dots, microreactor systems offer unparalleled control over nucleation and growth kinetics. Microfluidic environments enable precise manipulation of reaction parameters including temperature, reactant concentration, and mixing time, which directly influence particle size, crystallinity, and optical properties [16-17]. This level of control is especially valuable for biomedical applications where uniformity and stability are critical, such as imaging, biosensing, and photothermal therapy.

3.4 Hybrid and Stimuli-Responsive Nanocarriers

Microfluidics also facilitates the fabrication of hybrid and stimuli-responsive nanocarriers, combining the strengths of multiple material classes to achieve multifunctional performance. Polymer–lipid hybrid nanoparticles, exosomes synthesized or modified on-chip, and smart nanomaterials designed to respond to environmental cues—such as pH, light, temperature, or enzymatic activity—benefit from the tight reaction control offered by microfluidic systems. These platforms enable the incorporation of responsive functionalities with high precision, paving the way for next-generation nanocarriers capable of targeted, adaptive, and programmable drug delivery [18].

4. Process Control and Optimization

Effective nanoparticle synthesis in microfluidic systems relies heavily on the precise control of operational parameters, particularly flow rate ratios (FRR) and total flow rate (TFR). These parameters directly influence mixing intensity, nucleation rates, and ultimately the physicochemical characteristics of the resulting nanoparticles. Higher FRRs typically promote rapid solvent displacement and smaller particle sizes, while adjustments in TFR can modulate polydispersity and production throughput. Alongside flow parameters, the architecture of the microfluidic device—whether a T-junction, Y-channel, or flow-focusing geometry—plays a critical role in determining mixing efficiency and shear dynamics, which together shape nanoparticle formation and stability [19].

To ensure robust and reproducible nanomanufacturing, modern microfluidic systems increasingly integrate real-time analytical tools. In-line sensors such as UV–Vis spectrometers, dynamic light scattering (DLS) probes, and Raman spectroscopy enable continuous monitoring of particle size, concentration, and chemical composition during synthesis. This real-time feedback is essential for maintaining quality control and implementing automated adjustments during continuous production. Moreover, systematic process optimization has been enhanced through the use of Design of Experiments (DoE), allowing researchers to evaluate multiple

parameters simultaneously, identify critical interactions, and develop optimized synthesis protocols tailored to specific nanoparticle platforms.

5. Scale-Up Strategies in Microfluidic Nanomanufacturing

Translating microfluidic nanoparticle synthesis from laboratory scale to industrial production presents several challenges, including device clogging, limited throughput, and the technical complexity of parallelizing multiple microchannels. Because individual microchannels produce nanoparticles in relatively small quantities, scaling up production requires innovative engineering strategies to maintain precision while increasing output. Two primary approaches—scaling-up and numbering-up—have emerged to address this need. Scaling-up focuses on increasing channel dimensions or flow capacities, but often compromises mixing quality, whereas numbering-up involves running many identical microchannels in parallel to preserve nanoscale control while boosting productivity [20-21].

Industrial adoption of microfluidics has been accelerated by the development of advanced platforms capable of Good Manufacturing Practice (GMP) compliance. These systems integrate precise flow control, in-line analytics, and robust materials to ensure nanoparticle consistency at large volumes. Notably, microfluidic manufacturing played a pivotal role in the large-scale production of lipid nanoparticles for mRNA vaccines during the COVID-19 pandemic, providing a real-world demonstration of the technology's scalability and reliability. Several FDA-approved nanomedicines now rely on microfluidic-assisted processes, highlighting the growing acceptance of this technique as a cornerstone of next-generation pharmaceutical manufacturing [21-22]. Figure 1



Figure 1: Schematic Overview of Microfluidic Nanomanufacturing

6. Applications in Drug Delivery

Microfluidic technologies have opened new frontiers in drug delivery by enabling the production of highly uniform and customizable nanocarriers suited for a wide range of therapeutic applications. One of the most prominent uses lies in targeted drug delivery, where microfluidic-synthesized nanoparticles can be engineered to selectively accumulate in cancer tissues, combat infectious diseases, or cross complex barriers such as the blood–brain barrier for central nervous system (CNS) therapies. The precise control over particle size, surface charge, and functionalization makes these systems ideal for enhancing biodistribution and minimizing off-target effects. Additionally, microfluidics supports the development of controlled-release formulations, enabling sustained or stimuli-triggered drug delivery that improves therapeutic outcomes and reduces dosing frequency [23-24].

Another rapidly growing application is personalized nanomedicine. Microfluidic platforms enable rapid, small-volume formulation adjustments tailored to individual patient needs, making patient-specific nanoformulations more feasible than ever before. Beyond therapeutic delivery, microfluidic-synthesized nanocarriers are also finding value in theranostic applications, where diagnostic imaging agents and therapeutic compounds are integrated into a single nanostructure. This dual-function approach allows real-time monitoring of drug distribution and treatment response, paving the way for more adaptive and precision-guided therapies [25-26].

7. Integration with Emerging Technologies

The convergence of microfluidics with emerging technologies is accelerating advancements in pharmaceutical nanomanufacturing. The integration of artificial intelligence and machine learning (AI/ML) enables predictive design of nanoparticle formulations and automated optimization of synthesis parameters, significantly reducing experimental time and improving reproducibility. Similarly, organ-on-chip systems provide physiologically relevant microenvironments for rapid screening of nanoformulations, offering more accurate preclinical insights compared to conventional cell culture models.

In parallel, the adoption of 3D printing has revolutionized microfluidic device fabrication by allowing rapid prototyping of complex channel designs, enhanced customization, and cost-effective production. Moreover, the emergence of IoT-enabled continuous-flow platforms supports real-time data acquisition and remote process control, paving the way for autonomous nanosynthesis systems. Together, these advancements position microfluidics as a central hub within a broader digital and engineering ecosystem designed to modernize pharmaceutical manufacturing [27-28].

8. Challenges and Limitations

Despite its transformative potential, microfluidic nanomanufacturing faces several technical and regulatory challenges that limit widespread industrial adoption. Device fouling and

clogging remain persistent issues, particularly when working with viscous formulations or high particle concentrations. Material compatibility challenges—such as solvent absorption in PDMS or chemical degradation of thermoplastics—can further impact device performance and product quality. In addition, the cost and complexity of microfluidic fabrication, along with the need for specialized equipment, hinder large-scale deployment in manufacturing facilities [29-30].

Another critical challenge involves ensuring batch-to-batch consistency and establishing rigorous quality control standards suitable for clinical-grade production. While microfluidics excels at producing uniform nanoparticles on a small scale, translating these advantages into GMP-compliant workflows requires robust process validation and regulatory harmonization. These barriers must be addressed to unlock the full potential of microfluidic nanomanufacturing in commercial pharmaceutical applications [31-32].

9. Future Perspectives

The future of pharmaceutical nanomanufacturing is poised to be reshaped by the evolution of autonomous microfluidic systems capable of continuous, hands-free nanosynthesis. These "microfluidic factories" will integrate advanced sensors, automated controls, and AI-driven decision-making to maintain optimal synthesis conditions without human intervention, ensuring unmatched precision and consistency [33-34]. In parallel, breakthroughs in ultra-high-throughput parallelization will enable microfluidic platforms to meet global demands for vaccines and biologics, supporting rapid-response manufacturing during pandemics or large-scale therapeutic rollouts. The development of smart microreactors equipped with self-correcting algorithms represents another promising advancement, allowing systems to detect deviations in real time and instantly adjust parameters to maintain product quality.

As microfluidic-based nanomedicines progress toward clinical translation, regulatory harmonization will become increasingly important. Establishing global standards for device materials, process validation, and quality control will streamline approval pathways and encourage broader adoption by the pharmaceutical industry. These future developments collectively signal a shift toward more intelligent, efficient, and scalable nanomanufacturing ecosystems driven by microfluidic innovation [35-36].

10. Conclusion

Microfluidics has emerged as a transformative force in pharmaceutical nanomanufacturing, providing unparalleled control over nanoparticle synthesis, enhancing reproducibility, and enabling continuous and scalable production. By overcoming long-standing limitations of conventional bulk methods, microfluidic platforms have accelerated the development of sophisticated drug delivery systems with improved uniformity, targeting capabilities, and therapeutic performance. The integration of real-time analytics, automated optimization, and

advanced fabrication technologies further strengthens microfluidics as a cornerstone of next-generation nanomedicine.

As the field moves forward, the continued convergence of microfluidics with AI, IoT, and smart reactor technologies will drive significant improvements in manufacturing flexibility and throughput. With ongoing advancements and increasing regulatory alignment, microfluidic nanomanufacturing is well-positioned to become a central pillar in producing clinically translatable, scalable, and highly controlled drug delivery platforms for global healthcare needs.

Reference

1. Kara, A., Vassiliadou, A., Ongoren, B., Keeble, W., Hing, R., Lalatsa, A., & Serrano, D. R. (2021). Engineering 3D printed microfluidic chips for the fabrication of nanomedicines. *Pharmaceutics, 13*(12), 2134.
2. Abedinoghli, D., Charkhpour, M., Osouli-Bostanabad, K., Selselehjonban, S., Emami, S., Barzegar-Jalali, M., & Adibkia, K. (2018). Electrosprayed nanosystems of carbamazepine—PVP K30 for enhancing its pharmacologic effects. *Iranian Journal of Pharmaceutical Research, 17*, 1431–1443.
3. Barenholz, Y. (2012). Doxil®—The first FDA-approved nano-drug: Lessons learned. *Journal of Controlled Release, 160*(2), 117–134.
4. British Standards Institute. (2007). *Terminology for nanomaterials*. London, UK.
5. Bosetti, R., & Jones, S. L. (2019). Cost–effectiveness of nanomedicine: Estimating the real size of nano-costs. *Nanomedicine, 14*(11), 1367–1370.
6. Reports and Data. (2020). *Peptide therapeutics market* (p. 294). https://www.reportsanddata.com/report-detail/peptide-therapeutics-market
7. Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016). Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. *Pharmaceutical Research, 33*, 2373–2387.
8. Germain, M., Caputo, F., Metcalfe, S., Tosi, G., Spring, K., Åslund, A. K. O., Pottier, A., Schiffelers, R., Ceccaldi, A., & Schmid, R. (2020). Delivering the power of nanomedicine to patients today. *Journal of Controlled Release, 326*, 164–171.
9. Anselmo, A. C., & Mitragotri, S. (2019). Nanoparticles in the clinic: An update. *Bioengineering & Translational Medicine, 4*, e10143.
10. Forssen, E. A. (1997). The design and development of DaunoXome® for solid tumor targeting in vivo. *Advanced Drug Delivery Reviews, 24*, 133–150.
11. Boswell, G. W., Buell, D., & Bekersky, I. (1998). AmBisome (liposomal amphotericin B): A comparative review. *Journal of Clinical Pharmacology, 38*, 583–592.
12. Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017). Liposomal formulations in clinical use: An updated review. *Pharmaceutics, 9*(2), 12.
13. Silverman, J. A., & Deitcher, S. R. (2013). Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. *Cancer Chemotherapy and Pharmacology, 71*, 555–564.

14. Liu, X., Jiang, J., Chan, R., Ji, Y., Lu, J., Liao, Y.-P., Okene, M., Lin, J., Lin, P., Chang, C. H., et al. (2019). Improved efficacy and reduced toxicity using a custom-designed irinotecan-delivering silicasome for orthotopic colon cancer. *ACS Nano, 13*, 38–53.
15. Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019). The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. *Nature Nanotechnology, 14*, 1084–1087.
16. Choi, Y. H., & Han, H.-K. (2018). Nanomedicines: Current status and future perspectives in drug delivery and pharmacokinetics. *Journal of Pharmaceutical Investigation, 48*, 43–60.
17. Martins, J. P., das Neves, J., de la Fuente, M., Celia, C., Florindo, H., Günday-Türeli, N., Popat, A., Santos, J. L., Sousa, F., Schmid, R., et al. (2020). The solid progress of nanomedicine. *Drug Delivery and Translational Research, 10*, 726–729.
18. Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021). Lipid-based nanoparticles in the clinic and clinical trials: From cancer nanomedicine to COVID-19 vaccines. *Vaccines, 9*(4), 359.
19. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. *Nature Reviews Drug Discovery, 20*, 101–124.
20. Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020). COVID-19 vaccine development and a potential nanomaterial path forward. *Nature Nanotechnology, 15*, 646–655.
21. Soares, S., Sousa, J., Pais, A., & Vitorino, C. (2018). Nanomedicine: Principles, properties, and regulatory issues. *Frontiers in Chemistry, 6*, 360.
22. Selselehjonban, S., Garjani, A., Osouli-Bostanabad, K., Tanhaei, A., Emami, S., Adibkia, K., & Barzegar-Jalali, M. (2019). Physicochemical and pharmacological evaluation of carvedilol–Eudragit® RS100 electrosprayed nanostructures. *Iranian Journal of Basic Medical Sciences, 22*, 547–556.
23. Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2010). Nanomedicine. *New England Journal of Medicine, 363*, 2434–2443.
24. Khurana, A., Allawadhi, P., Khurana, I., Allwadhi, S., Weiskirchen, R., Banothu, A. K., Chhabra, D., Joshi, K., & Bharani, K. K. (2021). Role of nanotechnology behind the success of mRNA vaccines for COVID-19. *Nano Today, 38*, 101142.
25. Ahn, J., Ko, J., Lee, S., Yu, J., Kim, Y., & Jeon, N. L. (2018). Microfluidics in nanoparticle drug delivery: From synthesis to pre-clinical screening. *Advanced Drug Delivery Reviews, 128*, 29–53.
26. Fornaguera, C., & García-Celma, M. J. (2017). Personalized nanomedicine: A revolution at the nanoscale. *Journal of Personalized Medicine, 7*(4), 12.
27. Tapeinos, C., Battaglini, M., & Ciofani, G. (2017). Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. *Journal of Controlled Release, 264*, 306–332.

28. Fonseca-Santos, B., Gremião, M. P. D., & Chorilli, M. (2015). Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease. *International Journal of Nanomedicine, 10*, 4981–5003.
29. Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015). Advances and challenges of liposome-assisted drug delivery. *Frontiers in Pharmacology, 6*, 286.
30. Fenton, O. S., Olafson, K. N., Pillai, P. S., Mitchell, M. J., & Langer, R. (2018). Advances in biomaterials for drug delivery. *Advanced Materials, 30*, 1705328.
31. Sarfraz, M., Afzal, A., Yang, T., Gai, Y., Raza, S. M., Khan, M. W., Cheng, Y., Ma, X., & Xiang, G. (2018). Development of dual drug-loaded nanosized liposomal formulation by a reengineered ethanolic injection method and its pre-clinical pharmacokinetic studies. *Pharmaceutics, 10*(3), 151.
32. Sedighi, M., Sieber, S., Rahimi, F., Shahbazi, M.-A., Rezayan, A. H., Huwyler, J., & Witzigmann, D. (2019). Rapid optimization of liposome characteristics using a combined microfluidics and design-of-experiment approach. *Drug Delivery and Translational Research, 9*, 404–413.
33. Lalatsa, A., Schätzlein, A. G., & Uchegbu, I. F. (2019). Drug delivery across the blood–brain barrier. In *Comprehensive Biotechnology* (pp. 628–637). Elsevier.
34. Fernández-García, R., Lalatsa, A., Statts, L., Bolás-Fernández, F., Ballesteros, M. P., & Serrano, D. R. (2020). Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale. *International Journal of Pharmaceutics, 573*, 118817.
35. Rai, S., Pandey, V., & Rai, G. (2017). Transfersomes as versatile and flexible nano-vesicular carriers in skin cancer therapy: The state of the art. *Nano Reviews & Experiments, 8*, 1325708.
36. Opatha, S. A. T., Titapiwatanakun, V., & Chutoprapat, R. (2020). Transfersomes: A promising nanoencapsulation technique for transdermal drug delivery. *Pharmaceutics, 12*(9), 855.